HTG Changes Name to HTG Molecular Diagnostics

TUCSON, Ariz.--(BUSINESS WIRE)-- HTG, Inc., provider of molecular technology solutions, today announced it has officially changed its name to HTG Molecular Diagnostics. The company, formerly known as High Throughput Genomics or HTG, made the change to convey the company’s strategic vision and direction in providing molecular testing capabilities for clinical researchers, pharmaceutical clinical development and clinical testing laboratories. This announcement comes on the heels of a series D financing round which the company closed last month.

HTG’s clinical sample-based testing solutions consist of multiplexed and multi-parameter assays for precise, cost-effective, and rapid management of mRNA, miRNA, gene fusions, translocations, and single nucleotide variants. The company is working with many tumor types and initial, proprietary programs are focused in melanoma, lymphoma and lung cancer.

“We’re excited about the future of HTG Molecular Diagnostics and will continue to focus on supporting our customers in advancing their research, developing new drugs and finding better treatment options for patients,” said TJ Johnson, chief executive officer, HTG Molecular Diagnostics. “Personalized healthcare is being practiced every day and we strive to play a part in helping to advance molecular medicine by providing the next generation in molecular testing.”

About HTG Molecular Diagnostics

HTG Molecular Diagnostics is a leading provider of molecular-based solutions for gene expression profiling, miRNA and mRNA measurement, translational medicine and diagnostic applications. The Company’s qNPA™ molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based in Tucson, Arizona. Additional information is available at


Media Contact:
Schwartz Communications, Inc.
Risa Burgess/Lauren Petit, 781-684-0770
[email protected]
Company Contact:
HTG Molecular Diagnostics
TJ Johnson, 520-547-2827
chief executive officer
[email protected]

KEYWORDS:   United States  North America  Arizona

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Oncology  Pharmaceutical  Other Health  Research  Science